{
  "id": 483756,
  "title": "Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston",
  "url": "https://urgent.news/2026/08/10/helus-pharma-to-participate-at-the-canaccord-genuity-46th-annual",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T16:04:04.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/helus-pharma-to-participate-at-the-canaccord-genuity-46th-annual-growth-conference-in-boston"
  },
  "original_language": "en",
  "account": null,
  "summary": "CEO Michael Halstead to participate in a fireside chat on Wednesday, August 12 at 12:00 p.m. EDT NEW YORK and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) — Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}